Methanesulfonic Acid Cinepazide Injection for Treatment of Acute Cerebral Infarction

NCT ID: NCT01851759

Last Updated: 2013-05-10

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 288 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-10-31
• Study Completion Date: 2014-08-31

Brief Summary

Using placebo as control, The purpose of this study is to evaluate the efficacy and safety of methanesulfonic acid cinepazide injection to relieve disabled degree of acute cerebral infarction patients, and explore the best safe and effective dose as well as dose method.

Detailed Description

The study will enroll 288 acute cerebral infarction patients. Patients will be assigned randomly to receive either Methanesulfonic acid cinepazide injection or placebo treatment. All patient in the study will receive standard of care treatment and clinical, diagnostic, laboratory, safety, and follow-up evaluations. Follow-up evaluations, including National Institute of Health stroke scale(NIHSS), Barthel index score and modified Rankin scale assessments, will be done periodically until 90 days after onset. The degree of disabled improved will be a primary measure of drug effectiveness.

Conditions

Ischemic Stroke

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Cinepazide, Stroke, Injection

Test drug：Methanesulfonic acid cinepazide injection（5ml/125mg）

Group Type: EXPERIMENTAL

cinepazide

Intervention Type: DRUG

2 branches of Methanesulfonic acid cinepazide injection were matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day.

1 branch of simulation agent of Methanesulfonic acid cinepazide injection was matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day.

palcebo,Stroke,Injection

Placebo：simulation agent of Methanesulfonic acid cinepazide injection（5ml sterile water for injection）

Group Type: PLACEBO_COMPARATOR

placebo

Intervention Type: DRUG

2 branches of simulation agent of Methanesulfonic acid cinepazide injection were matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day.

1 branch of simulation agent of Methanesulfonic acid cinepazide injection were matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day.

Interventions

cinepazide

2 branches of Methanesulfonic acid cinepazide injection were matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day.

1 branch of simulation agent of Methanesulfonic acid cinepazide injection was matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day.

Intervention Type: DRUG

placebo

2 branches of simulation agent of Methanesulfonic acid cinepazide injection were matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day.

1 branch of simulation agent of Methanesulfonic acid cinepazide injection were matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day.

Intervention Type: DRUG

Other Intervention Names

Methanesulfonic acid cinepazide injection; simulation agent of Methanesulfonic acid cinepazide

Eligibility Criteria

Inclusion Criteria

1. Age between 40 and 75 years old，male/ female；

2. The clinical diagnosis of first onset patients with anterior circulation infarction or who have suffered from stroke in history and complete recover from neurologic impairment (mRS score <2 before this disease）

3. Patients is proved by head skull CT and cerebral hemorrhage was excluded；

4. course of disease≤72h，the NIHSS score is ≥7 and ≤22；

5. Patients who voluntarily sign written informed consent. -

Exclusion Criteria

1. Patients who suffer from cerebral infarction accompanied by disorder of consciousness, posterior circulation infarction, lacunar infarction and transient ischemic attack.

2. Patients who suffer from brain arteritis, brain tumor, brain injury, intracranial infection, brain parasitic disease, and so on . Patients who suffer from cardiac diseases such as rheumatic heart disease, coronary heart disease with atrial fibrillation .

3. Patients who suffer from severe complications, and expected survival period is within three months.

4. Patients require thrombolysis, anticoagulation, anti- fibrosis treatment .

5. Patients who suffer from serious brain artery stenosis that should go through interventional therapy .

6. Patients whose white blood cells or neutrophils is below the lower limit of the normal reference value .

7. Patients who have bleeding tendency or suffered from serious bleeding in 3 months.

8. Patients who have severe cardiac, liver and kidney disease, or whose kidney and liver function tests was abnormal（ALT,AST≥1.5 times of upper normal limit，Cr>upper normal limit）.

9. Patients who have complications of malignant tumor, serious or progressive disease in blood, digestion or other system.

10. Patients who have complications of mental illness un can not or do not want willing to cooperate .

11. Doubt or does have alcohol, drug abuse history

12. Allergic constitution or allergic to the test drug ingredients .

13. Pregnancy and lactation women or those who has a recent fertility plan

14. Patients who have participated in other clinical experiments three months before this test.

15. The patients who is unsuitable to participate in the clinical test in the view of researchers

• Minimum Eligible Age: 40 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Xijing Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Gang Zhao, Doctor

Role: PRINCIPAL_INVESTIGATOR

Xijing Hospital

Locations

Xijing Hospital

Xi'an, Shaanxi, China

Countries

China

Central Contacts

Gang Zhao, Doctor

Role: CONTACT

zhaogang@fmmu.edu.cn

Facility Contacts

Gang Zhao

Role: primary

zhaogang@fmmu.edu.cn

02984775361

Other Identifiers

xijing005

Identifier Type: -

Identifier Source: org_study_id